BMS Bets Its Biggest Oral Drug Can Do More Than Clear Skin

Efficacy is only half the equation. What makes Sotyktu's pitch interesting is how it works, and what it doesn't do.

If you've followed rheumatology drugs, you know JAK inhibitors. Tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are already approved for psoriatic arthritis. They work by blocking enzymes called Janus kinases, which relay inflammatory signals inside cells. The problem? Traditional JAK inhibitors are like using a shotgun when you need a scalpel. They hit JAK1, JAK2, JAK3, and TYK2 all at once, which can lead to broader immune suppression and safety concerns.

Sotyktu takes a fundamentally different approach. Instead of jamming itself into the common catalytic site that all JAK family members share (picture four doors with nearly identical locks), it binds to a regulatory region unique to TYK2 called the pseudokinase domain. This allosteric mechanism locks TYK2 in an "off" position with 100- to 2,000-fold selectivity over JAK1, JAK2, and JAK3 in lab tests.

The practical result? In PsA-2, serious adverse events hit just 1.9% of Sotyktu patients versus 1.0% on placebo. Discontinuations due to side effects were only 2.2%. For comparison, the apremilast (Otezla) reference arm in the same trial saw 10.5% of patients drop out due to adverse events. That's a striking gap.

A Crowded Room With an Empty Chair

Psoriatic arthritis is not an underserved market. It's packed with biologics: Cosentyx, Taltz, Tremfya, Skyrizi, and the soon-to-be-biosimilar Stelara all compete here. JAK inhibitors like Rinvoq offer oral convenience. Methotrexate remains a cheap, if imperfect, first-line workhorse.

So where does Sotyktu fit? The answer is in the intersection of two things patients and doctors want: an oral pill with a cleaner safety profile than existing oral options. Apremilast is oral but has tolerability issues (hello, 10.5% dropout rate). JAK inhibitors are oral but carry FDA boxed warnings about cardiovascular events, malignancies, and blood clots. Sotyktu could thread that needle.

BMS's Senior VP Roland Chen has positioned the drug as a potential first-line oral option for psoriatic arthritis, aimed squarely at the gap between "not potent enough" and "safety concerns."

The Pipeline Isn't Standing Still

Sotyktu won't have this lane to itself forever. Sonelokimab, a nanobody drug (smaller than traditional antibodies, designed to penetrate dense joint tissue more effectively), posted impressive Phase 2 results: nearly 50% of patients hit ACR50 response versus 20% on placebo. Two Phase 3 trials are recruiting now.

There's also zasocitinib, another pipeline candidate that showed over 50% ACR20 response in Phase 2, with Phase 3 studies running through 2028. Even tirzepatide (the GLP-1 drug behind Mounjaro and Zepbound) is being explored for psoriatic arthritis, because apparently that drug wants to treat everything.

Why March 6 Matters for BMS's Bigger Story

Bristol Myers Squibb is navigating one of the trickiest transitions in big pharma. Its legacy drugs are bleeding revenue to generics, while its Growth Portfolio (which includes Sotyktu, Camzyos, Reblozyl, and the recently acquired Cobenfy) grew 16% in Q1 2025 to $5.6 billion. The company is spending nearly $10 billion annually on R&D.

A psoriatic arthritis approval for Sotyktu won't single-handedly fix any of that. But it would validate oral TYK2 inhibition beyond dermatology, open a larger addressable market, and give BMS a differentiated asset in a category where safety anxieties around existing oral drugs create a real commercial opportunity.

Regulatory submissions are also under review in the EU, Japan, and China, so a U.S. green light could accelerate global momentum.

The FDA has three days to make its call. BMS has a lot riding on the answer.

The FDA Wants Fake Brain Surgery Before It'll Approve This Gene Therapy

The FDA told uniQure its promising Huntington's gene therapy needs a sham brain surgery trial before approval, torching the stock by 40%. The resulting ethical and regulatory showdown could reshape the future of every gene therapy that targets the brain.